

14. The method of Claim 11, wherein said chimeric anti-CD20 antibody is produced by a transfectoma which has been deposited in TCAE8, ATCC deposit number 69119.

C1
cont
15. The method of Claim 14, wherein the at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone.--

IN THE ABSTRACT:

Cancel the current Abstract and substitute the following therefor:

C2
--A method of treating B-cell lymphoma using a chimeric anti-CD20 antibody that provides for substantially total peripheral B-cell depletion at a dosage ranging from about 0.4 to 20 mg/kg body weight within about 24 hours post-administration, and a chemotherapeutic agent is provided.--